Integrated Biopharma Inc (NYSE:INB): Institutional Investors Are Worried

September 16, 2018 - By Eula Gilbert

Sentiment for Integrated Biopharma Inc (NYSE:INB)

Integrated Biopharma Inc (NYSE:INB) institutional sentiment decreased to 0.47 in Q2 2018. Its down -1.28, from 1.75 in 2018Q1. The ratio is negative, as 8 investment managers increased and started new stock positions, while 17 sold and decreased stock positions in Integrated Biopharma Inc. The investment managers in our partner’s database now hold: 2.67 million shares, down from 2.74 million shares in 2018Q1. Also, the number of investment managers holding Integrated Biopharma Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 11 Increased: 5 New Position: 3.

Cohen & Steers Global Income Builder, Inc. is a closed-end equity mutual fund launched by Cohen & Steers Inc. The company has market cap of $. It is managed by Cohen & Steers Capital Management, Inc. It currently has negative earnings. The fund invests in the public equity markets across the globe.

The stock decreased 0.64% or $0.06 during the last trading session, reaching $9.33. About 64,524 shares traded or 2.37% up from the average. Cohen & Steers Global Income Builder, Inc (NYSE:INB) has declined 2.60% since September 16, 2017 and is downtrending. It has underperformed by 18.22% the S&P500.

Cutter & Co Brokerage Inc. holds 0.22% of its portfolio in Cohen & Steers Global Income Builder, Inc for 58,983 shares. Karpus Management Inc. owns 78,506 shares or 0.03% of their US portfolio. Moreover, Girard Partners Ltd. has 0.02% invested in the company for 11,411 shares. The Illinois-based Guggenheim Capital Llc has invested 0.02% in the stock. Stifel Financial Corp, a Missouri-based fund reported 524,980 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.